SS-31 timeline: what research and user reports show
SS-31, studied clinically as elamipretide, concentrates directly in mitochondria and has been tested in human trials for primary mitochondrial disease, giving it more controlled human grounding than many research peptides.
Weeks 1 to 2: adjustment reports
Similar to MOTS-C, reports sometimes describe a brief adjustment window as mitochondrial activity shifts, generally milder and shorter than what is commonly reported with MOTS-C.
Weeks 4 to 8: cumulative reports
Reports increasingly describe steadier energy and improved exercise endurance in this window, consistent with SS-31's studied role in supporting mitochondrial membrane function.
Common questions
How does this compare to MOTS-C? Both target mitochondrial function but through different mechanisms, SS-31 by stabilizing mitochondrial membranes directly and MOTS-C through AMPK signaling. See our MOTS-C timeline for that comparison.
For mechanism, dosing reference and citations, see the SS-31 reference page.